Latest news with #GrowthConference
Yahoo
3 days ago
- Business
- Yahoo
ICF to Present at the Canaccord Genuity 45th Annual Growth Conference
RESTON, Va., Aug. 6, 2025 /PRNewswire/ -- ICF (NASDAQ:ICFI), a leading global solutions and technology provider, today announced its participation at the Canaccord Genuity 45th Annual Growth Conference in Boston. ICF Chief Executive Officer John Wasson and Executive Vice President of Energy, Environment and Infrastructure Anne Choate will participate in a fireside chat at 9:30 a.m. Eastern Time on Wednesday, August 13. A live webcast of the fireside chat will be available at replay will be available for 90 days following the conference. About ICF ICF is a leading global solutions and technology provider with approximately 9,000 employees. At ICF, business analysts and policy specialists work together with digital strategists, data scientists and creatives. We combine unmatched industry expertise with cutting-edge engagement capabilities to help organizations solve their most complex challenges. Since 1969, public and private sector clients have worked with ICF to navigate change and shape the future. Learn more at Caution Concerning Forward-looking Statements Statements that are not historical facts and involve known and unknown risks and uncertainties are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such statements may concern our current expectations about our future results, plans, operations and prospects and involve certain risks, including those related to the government contracting industry generally; our particular business, including our dependence on contracts with U.S. federal government agencies; and our ability to acquire and successfully integrate businesses. These and other factors that could cause our actual results to differ from those indicated in forward-looking statements are included in the "Risk Factors" section of our securities filings with the Securities and Exchange Commission. The forward-looking statements included herein are only made as of the date hereof, and we specifically disclaim any obligation to update these statements in the future. Investor information contact:Lynn Morgen, AdvisIRy Partners, +1.212.750.5800 or David Gold, AdvisIRy Partners, +1.212.750.5800 Company information contact:Lauren Dyke, ICF, +1.571.373.5577 View original content to download multimedia: SOURCE ICF
Yahoo
28-07-2025
- Business
- Yahoo
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
MASON, Ohio, July 28, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference. AtriCure's management is scheduled to present on Tuesday, August 12, 2025, at 2:30 p.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X @AtriCure. View source version on Contacts Angie WirickAtriCure, Financial Officer(513) 755-5334awirick@ Marissa BychGilmartin GroupInvestor Relationsmarissa@
